



International Journal of Diabetes and Endocrinology

International Journal of Diabetes and Endocrinology

[Home](#) | [About](#) | [Archive](#) | [Submission](#) | [Special Issues](#) | [Editorial Board](#) | [Reviewers](#) | [Join](#) | [Events](#) | [Contact](#)[Home](#) > [Journals](#) > [International Journal of Diabetes and Endocrinology](#) > [Editorial Board Members](#)

Editorial Board Members (16)

Assoc. Prof. Sayeeda Rahman

School of Medicine, American University of Integrative Sciences, Bridgetown, Barbados



Dr. Andrea Dehn-Hindenberg

Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School (MHH), Hannover, Germany



Dr. Mayank Choubey

Department of Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, United States



Dr. Ratnakar Tiwari

Feinberg School of Medicine, Division of Nephrology and Feinberg Cardiovascular and Renal Research Institute, Northwestern University, Evanston, United States



Ian Martins

Sarich Neuroscience Research Institute, Nedlands, Australia

Ke Wu

Division of Cancer Research and Training, Charles Drew University of Medicine and Science, David Geffen UCLA School of Medicine, and UCLA Jonsson Comprehensive Cancer Center, Los Angeles, United States

Y. Miles Yu

Department of Pediatrics, Nemours Children's Hospital, Orlando, United States

Assist. Prof. Onur Ertik

Department of Chemistry, Bursa Technical University, Bursa, Turkey



Prof. Daniel A. Montes-Galindo

Faculty of Chemical Sciences, University of Colima, Colima, Mexico

Assoc. Prof. Yumin Ma

Department of Endocrinology and Metabolism, Affiliated Hospital of Yangzhou University, Yangzhou, China



Assoc. Prof. Li Tian

West China Hospital, Sichuan University, Chengdu, China

Yue Zheng

Heart Center, Nankai University, Tianjin, China

Assoc. Prof. Pankaj Jain

Department of Pharmacology, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Shirpur, India



Assoc. Prof. Davina Hijam

Department of Biochemistry, Regional Institute of Medical Sciences, Imphal, India




Venkatraman Rajkumar

Endocrinology, Diabetes, Geriatric Medicine, Banting Clinic For Diabetes and Endocrinology, Chennai, India

Archive

2024, Volume 9 >

2023, Volume 8 

Issue 4, Dec.

Issue 3, Sep.

Issue 2, Jun.

Issue 1, Mar.

2022, Volume 7 >

2021, Volume 6 >

2020, Volume 5 >

2019, Volume 4 >

2018, Volume 3 >

2017, Volume 2 >

2016, Volume 1 >

Volume 8, Issue 3, September 2023

 [Open Access](#)

High Lipoprotein (a) Concentration Is Associated with Diabetic Nephropathy

Meutia Atika Faradilla, Karina Shasri Anastasya, Yohana, Meiyanti, Andira Larasari, Daniella Satyasari, Endrico Xavierees Tungka

Issue: Volume 8, Issue 3, September 2023

Pages: 37-41

Received: 6 August 2023

Accepted: 4 September 2023

Published: 13 September 2023

DOI: [10.11648/j.ijde.20230803.11](https://doi.org/10.11648/j.ijde.20230803.11)

Downloads: 55

Views: 490

Abstract: *Aims:* Lipoprotein (a) [Lp(a)] has been well recognized as a risk factor for both micro and macrovascular complications in diabetes, due to its atherogenic effects. Studies suggested that serum lipoprotein (a) [Lp(a)] concentration may take part in the aggravation of diabetic nephropathy. Accumulating evidence suggests that higher serum Lp(a) may be... [Show More](#)



[Download PDF](#)



[View Online](#)

 [Open Access](#)

Michigan Neurologic Scale in Early Screening for Diabetic Neuropathy in Patients with Type 2 Diabetes Mellitus

Na Li, Xuemei Wang

Issue: Volume 8, Issue 3, September 2023

Pages: 42-44

Received: 1 September 2023

Accepted: 13 September 2023

Published: 25 September 2023

DOI: [10.11648/j.ijde.20230803.12](https://doi.org/10.11648/j.ijde.20230803.12)

Downloads: 23

Views: 374

Abstract: *Objective:* To apply the Michigan Neuropathy Screening Scale in social health to achieve early detection, intervention, and treatment of diabetic neuropathy in patients with type 2 diabetes mellitus. *Methods:* Fifty-eight patients with type 2 diabetes mellitus with weakened dorsalis pedis arteries attending the outpatient clinic of Huangtian Communit... [Show More](#)



[Download PDF](#)



[View Online](#)

High Lipoprotein (a) Concentration Is Associated with Diabetic Nephropathy

Meutia Atika Faradilla¹, Karina Shasri Anastasya², Yohana¹, Meiyanti³, Andira Larasari⁴, Daniella Satyasari⁵, Endrico Xavierees Tungka¹

¹Department of Biochemistry, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia

²Department of Nutrition, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia

³Department of Pharmacology and Medical Pharmacy, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia

⁴Department of Neurology, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia

⁵Department of Psychiatry, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia

Email address:

meutia.atika@trisakti.ac.id (Meutia Atika Faradilla)

To cite this article:

Meutia Atika Faradilla, Karina Shasri Anastasya, Yohana, Meiyanti, Andira Larasari, Daniella Satyasari, Endrico Xavierees Tungka. High Lipoprotein (a) Concentration Is Associated with Diabetic Nephropathy. *International Journal of Diabetes and Endocrinology*. Vol. 8, No. 3, 2023, pp. 37-41. doi: 10.11648/j.ijde.20230803.11

Received: August 6, 2023 **Accepted:** September 4, 2023; **Published:** September 13, 2023

Abstract: *Aims:* Lipoprotein (a) [Lp(a)] has been well recognized as a risk factor for both micro and macrovascular complications in diabetes, due to its atherogenic effects. Studies suggested that serum lipoprotein (a) [Lp(a)] concentration may take part in the aggravation of diabetic nephropathy. Accumulating evidence suggests that higher serum Lp(a) may be associated with impaired renal function in populations. Therefore this study comprehensively evaluates the association between Lipoprotein (a) and diabetic nephropathy in patients with type 2 diabetes mellitus. *Methods:* One hundred subjects (50 with diabetic nephropathy and 50 type 2 diabetes mellitus without nephropathy) were studied. The examination used blood serum where lipoprotein a used the ELISA method. Nonpara- metric Mann–Whitney U-tests were used to compare the levels of lipoprotein a in diabetic nephropathy and Type 2 DM without diabetic nephropathy. *Results:* Lipoprotein a in the diabetic nephropathy group was higher when compared to the type 2 DM group without nephropathy (OR = 2.8; 95%; CI = 1.84-12.07). *Conclusion:* High lipoprotein (a) concentration are associated with diabetic nephropathy. Lipoprotein may reflect chronic underlying pathophysiological processes involved in development of complications of T2DM and serum Lp(a) can be considered as a promising predictive factor for the diagnosis of earlier diabetic nephropathy.

Keywords: Lipoprotein (a), Diabetic Nephropathy, Type 2 Diabetes Mellitus

1. Introduction

Patients with type 2 diabetes mellitus (T2DM) are vulnerable to kidney dysfunction, namely diabetic nephropathy [1]. The increasing incidence of diabetes mellitus globally causes many people with type 2 diabetes mellitus to develop diabetic nephropathy [2]. Diabetic nephropathy has become one of the leading causes of end-stage renal disease (ESRD) As a common complication of T2DM all over the world [3]. It has been reported that currently, over 20% of patients with diabetes ultimately develop diabetic nephropathy, which has become a major cause of mortality in these patients [4]. Age, race, diabetes duration, hyperglycemia,

dyslipidemia, and hypertension are among the risk factors for diabetic nephropathy. However, determining residual risk factors for diabetic nephropathy remains clinically relevant for stratification and management of the disease [5].

Lipoprotein (a) [Lp(a)] has been well recognized as a risk factor of of both micro and macrovascular complications in diabetes, due to its atherogenic effects. Glycation of lipoproteins has been implicated to play a role in the pathogenesis of micro- and macro-vascular complications [6]. Lipoprotein (a) [Lp(a)], discovered in 1963, is plasma-based but has a special structure. It comprises a lipid-rich apolipoprotein (apo) B-containing lipoprotein and apo(a) [7]. The apo(a) gene is highly homologous to the plasminogen

gene, and it mainly encodes two tricyclic domains (KIV and KV), and an inactive proteasome domain. Plasma Lp(a) levels are not changed by the environment, but primarily depend on genetic factors, for example, chromosomal mutation of the LPA gene. [8]

Studies suggested that serum lipoprotein (a) [Lp(a)] concentration may take part in the aggravation of diabetic nephropathy. It has been shown that serum Lp(a) is associated with impaired renal function in populations with higher levels of serum Lp(a) and these studies also demonstrated that serum Lp(a) has a strong correlation with increased risk of complications in individuals with Type 2 diabetes [9-13]. It seems that serum Lp(a) can be considered as a promising predictive factor for the diagnosis of earlier diabetic nephropathy. Therefore, relationship between Lp(a) level and diabetic nephropathy remains undetermined. Further research is needed to investigate the exact role of Lp(a) in the progression of diabetic nephropathy. Additionally, more studies should be conducted to explore the potential of Lp(a) as a biomarker for early diagnosis of the disease.

Accordingly, in this study, we performed a case control study to comprehensively evaluate the association between Lp(a) and diabetic nephropathy in patients with T2DM.

2. Subjects, Materials and Methods

2.1. Subjects and Blood Collection

One hundred Type 2 diabetes mellitus patient as research subjects were divided into two groups, the case group of 50 patients who had been diagnosed with diabetic nephropathy and the control group of 50 patients who were diagnosed with type 2 diabetes mellitus without diabetic nephropathy. Collection of research sample data and blood samples was carried out at the Endocrine Polyclinic of the Government General Hospital (RSUP) H. Adam Malik Medan.

Inclusion criteria for the case group were patients who had been diagnosed with diabetic nephropathy, have history of diabetes for more than 7 years, diabetic retinopathy or impaired kidney function in family and lab results 2x persistent proteinuria in 3-6 months, which found microalbuminuria (30-300mg/g), macroalbuminuria (> 300mg/g), decreased eGFR (> 60ml/min/1.73m²). Inclusion criteria for the control group, patients diagnosed with type 2 diabetes mellitus without nephropathy and willing to sign an informed consent. Exclusion criteria were patients with end state renal disease, patients with impaired liver function, hematuria, pyuria and pregnant.

2.2. Intervention

In the study, anamnesis was carried out, looking at medical records, taking blood and urine samples and laboratory tests. Anamnesis, medical records, laboratory tests are used to

diagnose patients in the control and case groups. Diabetes duration, fasting blood glucose levels and 2 hours post prandial, urine microalbumin on the spot, HbA1C, creatinine and eGFR were also measured to assess subject characteristics. The examination used blood serum where lipoprotein a used the ELISA method. Examination of fasting blood sugar levels and 2 hours post prandial, HbA1C, creatinine using the COBAS automated analyzer and eGFR using the Modification of Diet in Renal Disease (MDRD) method.

2.3. Statistic Analysis

Statistical analyses were performed with SPSS 21.0. The values were expressed as mean standard deviation (SD). The normality test uses the Kolmogorov-Smirnov normality test. Nonparametric Mann-Whitney U-tests were used to compare the levels of lipoprotein a in diabetic nephropathy and Type 2 DM without diabetic nephropathy. The unpaired t test was used for analyzing other variables between the groups. A value of $p < 0.05$ was considered as statistically significant.

2.4. Ethical Clearance

The research protocol was approved by the Health Research Ethics Committee, Faculty of Medicine, University of North Sumatra. All study subjects signed written informed consent after being informed about the aims and benefits of the study.

3. Result

There were differences in subject characteristics between the diabetic nephropathy group and the type 2 DM group without nephropathy. Age in the diabetic nephropathy group was 59.40 ± 8.48 years, while in the type 2 DM group without diabetic nephropathy was 56.56 ± 9.72 years ($p = 0.472$). The duration of diabetes in the diabetic nephropathy group was 13.12 ± 5.26 years, while in the type 2 DM group without diabetic nephropathy was 2.96 ± 1.62 years ($p=0.000$). HbA1c in the diabetic nephropathy group was $8.07 \pm 2.15\%$ while in the type 2 DM group without diabetic nephropathy was $6.32 \pm 0.62\%$ ($p=0.000$). The fasting KGD in the diabetic nephropathy group was 170.72 ± 82.85 mg/dl while in the type 2 DM group without diabetic nephropathy it was 132.32 ± 24.66 mg/dl ($p=0.132$).

Postprandial blood sugar in the diabetic nephropathy group was 257.28 ± 100.88 mg/dl while in the group Type 2 DM without diabetic nephropathy was 212.52 ± 70.36 mg/dl ($p=0.171$). The creatinine in the diabetic nephropathy group was 0.92 ± 0.17 mg/dl while in the type 2 DM group without diabetic nephropathy it was 0.71 ± 0.13 mg/dl ($p=0.000$). eGFR in the diabetic nephropathy group was 73.72 ± 11.08 mL/min/1.73m² whereas in the type 2 DM group without diabetic nephropathy it was 103.76 ± 22.72 mL/min/1.73 m² ($p=0.000$) (Table 1).

Table 1. Subject characteristics.

Subject characteristics	Diabetic nephropathy	Type 2 DM without diabetic nephropathy	P Value
Age (years)	59.40 ± 8.48	56.56 ± 9.72	
Diabetes duration (years)	13.12 ± 5.26	2.96 ± 1.62	0.000*
HbA1c (%)	8.07 ± 2.15	6.32 ± 0.62	0.000*
Fasting blood sugar level (mg/dl)	170.72 ± 82.85	132.32 ± 24.66	0.132
Postprandial blood sugar (mg/dl)	257.28 ± 100.88	212.52 ± 70.36	0.171
Hemoglobin (g/dl)	10.87 ± 1.38	12.19 ± 1.33	0.001*
Creatinine (mg/dl)	0.92 ± 0.17	0.71 ± 0.13	0.000*
eGFR (mL/min/1.73 m ²)	73.72 ± 11.08	103.76 ± 22.72	0.000*

The lipoprotein a level in the diabetic nephropathy group was 46.12±26.92mg/dl while the lipoprotein a level in the type 2 DM group without diabetic nephropathy was 25.08±19.24mg/dl (p=0.040). The odds ratio (OR) for lipoprotein a is 2.8, this indicates that patients with diabetic

nephropathy tend to have lipoprotein a levels 2.8 times higher than in type 2 DM without nephropathy. From the results of the coefficient interval (CI) on the odds ratio, it can be seen that lipoprotein A plays a very significant role in diabetic nephropathy because the CI number is above 1 (table 2).

Table 2. Differences levels of bilirubin and lipoprotein a in the two groups.

	Diabetic nephropathy	Type 2 DM without diabetic nephropathy	P Value	OR Value
Lipoprotein a (mg/dl)	46.12 ± 26.92	25.08 ± 19.24	0.040	2.8 (95% CI=1.84-12.07)

4. Discussion

We demonstrated subject characteristic between diabetic nephropathy and type 2 diabetes mellitus without diabetic nephropathy. In This study show that, significant differences were found in the initial characteristics of the study subjects where the duration of diabetes tended to be longer than 10 years, HbA1c was found to be uncontrolled, fasting KGD and 2-hour PPG were high, hemoglobin and eGFR levels decreased and creatinine levels increased. It is appropriate that the increased duration of diabetes, uncontrolled HbA1c is known to be a risk factor for the progression of diabetic nephropathy [14].

Lipoprotein a has a greater role in the progression of diabetic nephropathy. This can be seen statistically from the results of the confidential interval (CI) on the odds ratio which shows that lipoprotein a has a strong influence. Lp(a) has an affinity for various components of the subendothelial matrix including proteoglycans, fibrinogen and fibronectin. Lp(a) also binds to lipoprotein-rich lipoproteins triglycerides, which can lead to accumulation of lipids in the artery walls. Research also shows that Lp(a) is more easily oxidized and accumulates in the artery walls causing atherosclerosis. Just like LDL, Lp(a) will undergo oxidative modification to become a substrate which is then captured by macrophages to form foam cells. Lp(a) can trigger inflammation leading to monocyte chemotaxis and expression of vascular adhesion molecules. Apo(a) has similarities with plasminogen which can trigger fibrinolysis so that it can interfere with the work of plasminogen and trigger thrombosis [15].

The lipoprotein (a) level in the diabetic nephropathy group was higher when compared to the type 2 diabetes mellitus group. This is because impaired kidney function can cause impaired excretion of lipoprotein a, so albuminuria sufferers will find an increase in serum lipoprotein a. As it is known that the kidney is the main excretion site of lipoprotein a [16]. This

is in accordance with Toro et al. Whereas type 2 diabetes patients show that microalbuminuria (nephropathy in the subclinical phase) or proteinuria (nephropathy in the advanced phase) is associated with increased levels of Lp(a) [17].

The mechanisms underlying the potential association between Lp(a) and diabetic nephropathy could also be multifactorial. the foremost explanation is that serum Lp(a) levels reflect a balance of Lp(a) synthesis within the liver and catabolism possibly involving the kidney [9]. Lp(a) levels were significantly increased compared to healthy controls, which were rapidly decreased after kidney transplantation but not after the initiation of hemolysis. As a result of the loss of functioning renal tissue, the increase in Lp(a) observed in CKD may be attributed to the involvement of the kidney in Lp(a) catabolism. This suggests that the kidney plays an important role in modulating plasma Lp(a) concentrations and that renal dysfunction could be a major contributing factor to the elevated levels of Lp(a) observed in CKD patients [18]. Besides, it has also been suggested that the increase in Lp(a) associated with protein-losing-related renal disease is likely to be a result of a general increase in protein synthesis by the liver due to high urinary protein loss rather than decreased catabolism. It remains unclear whether increased Lp(a) plays a key role in the pathogenesis of diabetic nephropathy or it is just a marker of impaired renal function [19].

Given the atherogenic role of Lp(a) and therefore the importance of glomerular atherosclerosis within the pathogenesis of diabetic nephropathy [20]. Lp(a) could also be involved in the progression of diabetic nephropathy via its atherogenic effect. An early study in vitro study showed that low concentrations of Lp(a) stimulated the expansion of mesangial cells, whereas higher concentrations had antiproliferative or toxic effects, which can both hurt the course of renal disease [21]. Another study showed that Lp(a) stimulated the growth of human mesangial cells and induced the activation of phospholipase C, which may therefore contribute to pathophysiology of renal disease [22]. Moreover,

oxidative stress has been confirmed that play a key role in the pathogenesis of diabetic renal complications [23]. Lp(a) was reported to induce the generation of oxygen-free radicals in vitro, which may partly contribute to kidney injury in diabetes [24]. Besides, Lp(a) is vulnerable to oxidative modification, resulting in the extensive formation of pro-inflammatory oxidized phospholipids, oxysterols, and oxidized lipid-protein adducts in Lp(a) particles, which can perpetuate kidney injury [25].

5. Conclusion

High lipoprotein (a) concentration are associated with diabetic nephropathy. Lipoprotein may reflect chronic underlying pathophysiological processes involved in development of complications of T2DM and serum Lp(a) can be considered as a promising predictive factor for the diagnosis of earlier diabetic nephropathy.

Acknowledgements

We are grateful to the research subjects who have helped to complete this research and to all colleagues who have provided input for the completion of this manuscript.

References

- [1] N. M. Selby and M. W. Taal, "An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines," *Diabetes Obes Metab*, vol. 22, pp. 3–15, 2020.
- [2] M. K. Sulaiman, "Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management," *Diabetol Metab Syndr*, vol. 11, pp. 1–5, 2019.
- [3] K. Umanath and J. B. Lewis, "Update on diabetic nephropathy: core curriculum 2018," *American journal of kidney diseases*, vol. 71, no. 6, pp. 884–895, 2018.
- [4] X.-X. Zhang, J. Kong, and K. Yun, "Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China: a meta-analysis of observational studies," *J Diabetes Res*, vol. 2020, 2020.
- [5] N. Nowak, "Protective factors as biomarkers and targets for prevention and treatment of diabetic nephropathy: from current human evidence to future possibilities," *J Diabetes Investig*, vol. 11, no. 5, pp. 1085–1096, 2020.
- [6] C. Lamina and N. C. Ward, "Lipoprotein (a) and diabetes mellitus," *Atherosclerosis*, vol. 349, pp. 63–71, 2022, doi: <https://doi.org/10.1016/j.atherosclerosis.2022.04.016>.
- [7] S. Tsimikas, "A test in context: lipoprotein (a) diagnosis, prognosis, controversies, and emerging therapies," *J Am Coll Cardiol*, vol. 69, no. 6, pp. 692–711, 2017.
- [8] D. P. Wilson, M. L. Koschinsky, and P. M. Moriarty, "Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein (a)," *Curr Opin Endocrinol Diabetes Obes*, vol. 28, no. 2, pp. 159–173, 2021.
- [9] J. C. Hopewell, R. Haynes, and C. Baigent, "The role of lipoprotein (a) in chronic kidney disease: thematic review series: lipoprotein (a): coming of age at last," *J Lipid Res*, vol. 59, no. 4, pp. 577–585, 2018.
- [10] J. Lin, M. P. Reilly, K. Terembula, and F. P. Wilson, "Plasma lipoprotein (a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria," *PLoS One*, vol. 9, no. 12, p. e114397, 2014.
- [11] H. Senba *et al.*, "Serum lipoprotein (a) levels and diabetic nephropathy among Japanese patients with type 2 diabetes mellitus," *J Diabetes Complications*, vol. 30, no. 5, pp. 923–927, 2016.
- [12] J. Yun *et al.*, "Lipoprotein (a) predicts a new onset of chronic kidney disease in people with Type 2 diabetes mellitus," *Diabetic Medicine*, vol. 33, no. 5, pp. 639–643, 2016.
- [13] F. Moosaie *et al.*, "Lp (a) and Apo-lipoproteins as predictors for micro-and macrovascular complications of diabetes: A case-cohort study," *Nutrition, Metabolism and Cardiovascular Diseases*, vol. 30, no. 10, pp. 1723–1731, 2020.
- [14] P. Muraliswaran, G. Aparna, P. Kanagavalli, and S. Srikanth, "Association between Microalbuminuria and HbA1C among known Type 2 Diabetic patients in puducherry population-A comparative study," *IOSR J Biotechnol Biochem*, vol. 2, no. 6, pp. 15–17, 2016.
- [15] K. Riches and K. E. Porter, "Lipoprotein (a): cellular effects and molecular mechanisms," *Cholesterol*, vol. 2012, 2012.
- [16] M. A. Faradilla, Y. Siregar, and D. Dalimunthe, "Penurunan Bilirubin Meningkatkan Oksidasi Lipoprotein A Pada Nefropati Diabetik," *Jurnal Kedokteran Syiah Kuala*, vol. 17, no. 3, pp. 152–158, 2017.
- [17] R. Toro, E. Segura, J. M. Nuñez-Cortes, J. C. Pedro-Botet, M. Quezada-Feijoo, and A. Mangas, "Relationship between lipoprotein (a) and micro/macro complications in type 2 diabetes mellitus: a forgotten target," *J Geriatr Cardiol*, vol. 12, no. 2, p. 93, 2015.
- [18] S. Rosas, M. Joffe, M. Wolfe, K. Brayman, and D. J. Rader, "Effects of renal replacement therapy on plasma lipoprotein (a) levels," *Am J Nephrol*, vol. 28, no. 3, pp. 361–365, 2008.
- [19] F. Kronenberg, "Causes and consequences of lipoprotein (a) abnormalities in kidney disease," *Clin Exp Nephrol*, vol. 18, pp. 234–237, 2014.
- [20] C.-C. Hung, J.-C. Tsai, H.-T. Kuo, J.-M. Chang, S.-J. Hwang, and H.-C. Chen, "Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials," *Rev Diabet Stud*, vol. 10, no. 2–3, p. 110, 2013.
- [21] S. Greiber, A. Krämer-Guth, H. Pavenstädt, M. Gutenkunst, P. Schollmeyer, and C. Wanner, "Effects of lipoprotein (a) on mesangial cell proliferation and viability," *Nephrology Dialysis Transplantation*, vol. 11, no. 5, pp. 778–785, 1996.
- [22] U. F. Mondorf *et al.*, "Lipoprotein (a) stimulates growth of human mesangial cells and induces activation of phospholipase C via pertussis toxin-sensitive G proteins," *Kidney Int*, vol. 55, no. 4, pp. 1359–1366, 1999.
- [23] A. Charlton, J. Garzarella, K. A. M. Jandeleit-Dahm, and J. C. Jha, "Oxidative stress and inflammation in renal and cardiovascular complications of diabetes," *Biology (Basel)*, vol. 10, no. 1, p. 18, 2020.

- [24] P. R. Hansen, A. Kharazmi, M. Jauhiainen, and C. Ehnholm, "Induction of oxygen free radical generation in human monocytes by lipoprotein (a)," *Eur J Clin Invest*, vol. 24, no. 7, pp. 497–499, 1994.
- [25] E. Orsó and G. Schmitz, "Lipoprotein (a) and its role in inflammation, atherosclerosis and malignancies," *Clin Res Cardiol Suppl*, vol. 12, pp. 31–37, 2017.